Patient‐reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain

Marrett, Elizabeth; Stargardt, Tom; Mavros, Panagiotis; Alexander, Charles M.

doi:10.1111/j.1463-1326.2009.01123.x

Cited by 68 publications

(73 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment-induced hypoglycemia represents a major concern in patients with diabetes and is associated with increased risk of cardiovascular events, decreased treatment satisfaction and health-related quality of life, and poor glycemic control (20,23). Both empagliflozin and linagliptin are associated with a low risk of hypoglycemia when given as monotherapy (6,18).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

et al. 2016

View full text Add to dashboard Cite

OBJECTIVETo evaluate the efficacy and safety of empagliflozin versus placebo as add-on therapy in patients with type 2 diabetes and inadequate glycemic control with linagliptin and metformin. RESEARCH DESIGN AND METHODSPatients with HbA 1c ‡8.0% and £10.5% ( ‡64 and £91 mmol/mol) while receiving stable-dose metformin received open-label linagliptin 5 mg (n = 606) for 16 weeks. Subsequently, those with HbA 1c ‡7.0 and £10.5% ( ‡53 and £91 mmol/mol) were randomized to receive double-blind, double-dummy treatment with empagliflozin 10 mg (n = 112), empagliflozin 25 mg (n = 111), or placebo (n = 110) for 24 weeks; all patients continued treatment with metformin and linagliptin 5 mg. The primary end point was the change from baseline in HbA 1c after 24 weeks of double-blind treatment. RESULTSAt week 24, empagliflozin significantly reduced HbA 1c (mean baseline 7.96-7.97% [63-64 mmol/mol]) versus placebo; the adjusted mean differences in the change from baseline with empagliflozin 10 and 25 mg versus placebo were 20.79% (95% CI -1.02, -0.55) (28.63 mmol/mol [-11.20, -6.07 mmol/mol]) and 20.70% (95% CI -0.93, -0.46) (27.61 mmol/mol [-10.18, -5.05 mmol/mol]), respectively (both P < 0.001). Fasting plasma glucose and weight were significantly reduced in both empagliflozin groups versus placebo (P < 0.001 for all comparisons). More patients receiving placebo than empagliflozin 10 and 25 mg reported adverse events during double-blind treatment (68.2%, 55.4%, and 51.8%, respectively). CONCLUSIONSEmpagliflozin treatment for 24 weeks improved glycemic control and weight versus placebo as an add-on to linagliptin 5 mg and metformin and was well tolerated.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Weight loss or avoiding weight gain is important to patients (19), with weight gain associated with decreased treatment satisfaction and health-related quality of life (20).…”

Section: Resultsmentioning

confidence: 99%

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Hypoglycemia in people with type -2 diabetes or fear of hypoglycemia creates difficulties in managing everyday life and might decrease quality of life [12][13][14][15][16]. Related data of current study is limited, although participants expressed fatigue and a feeling of not being able to perform tasks satisfactorily.…”

Section: Restrictions In Daily Life Related To Hypoglycemiamentioning

confidence: 70%

“…This in turn can present an obstacle to optimizing the blood glucose balance [11]. People who have repeated hypoglycemia problems reported a lower quality of life, less treatment satisfaction, and were more depressed than people not suffering from hypoglycemia [12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Untitled

Leksell

Andersson²,

Carlsson³

2014

DRTOA

View full text Add to dashboard Cite

show abstract

“…Studies have shown high prevalence of hypoglycaemia among patients with diabetes on treatment with oral hypoglycaemic agents or insulin (Marrett et al 2009;Murata et al 2005). Severe hypoglycaemia is associated with a 3-fold increased risk of mortality compared to non-severe hypoglycaemia (McCoy et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Cross-Cultural Adaptation and Linguistic Validation of the Hypoglycaemia Symptom Rating Scale (HypoSRQ) among Malaysian Patients with Diabetes Mellitus

Tan¹,

Sf²,

Aida³

et al. 2016

View full text Add to dashboard Cite

show abstract

Patient‐reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain

Abstract: Among patients with type 2 diabetes treated with OAHAs, self-reported hypoglycaemia and weight gain were associated with decreased treatment satisfaction and HRQoL. In addition, the presence of these SEs was associated with increased fear of hypoglycaemia.

Cited by 68 publications

References 24 publications

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

Untitled

Cross-Cultural Adaptation and Linguistic Validation of the Hypoglycaemia Symptom Rating Scale (HypoSRQ) among Malaysian Patients with Diabetes Mellitus

Contact Info

Product

Resources

About